Pfizer Biontech Covid Vaccine
-
{
- All
- News
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
Third Dose Of Pfizer's COVID-19 Vaccine 95.6% Effective: Study
A third dose of the vaccine against COVID-19 developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection.
-
"Fill And Finish": Pfizer BioNTech To Produce COVID-19 Vaccines In South Africa
Covid vaccine makers BioNTech and Pfizer said Wednesday they would produce their jab in South Africa from 2022, a first for the continent that could see much-needed immunisation drives pick up speed.
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
Third Dose Of Pfizer's COVID-19 Vaccine 95.6% Effective: Study
A third dose of the vaccine against COVID-19 developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection.
-
"Fill And Finish": Pfizer BioNTech To Produce COVID-19 Vaccines In South Africa
Covid vaccine makers BioNTech and Pfizer said Wednesday they would produce their jab in South Africa from 2022, a first for the continent that could see much-needed immunisation drives pick up speed.
